Earnings

Mirum Pharmaceuticals Announces Results From Cohort 2 Of Pivotal PROGRESS Study Of ATEBRIOZ

Oct 26, 2026 · 08:08 AM ET· updated 1h ago

- Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions- Mirum plans to submit an sNDA in H1 2027 to expand the ATEBRIOZ

Why It Matters

Mirum's medicine helped patients with a bone growth problem. Watch to see if the medicine gets approved by regulators next year.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MIRM81.53

+1.14 (+1.41%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.